MAIA Biotechnology Inc. (MAIA)

AI Score

Unlock

1.55

0.01 (0.65%)

At close: Apr 17, 2025, 3:58 PM

1.55

-0.08%

After-hours: Apr 17, 2025, 08:00 PM EDT

Dividends

No dividend history available for MAIA Biotechnology Inc..

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Related Stocks

Company	Dividend Yield

Dividend Rankings

MAIA News

2 weeks ago · MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - businesswire.com
3 weeks ago · MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - zacks.com
3 weeks ago · MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - businesswire.com
4 weeks ago · MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - businesswire.com
1 month ago · MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - businesswire.com
1 month ago · MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - businesswire.com
1 month ago · MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million - businesswire.com
1 month ago · MAIA Biotechnology Announces Private Placement of $2,715,000 - businesswire.com
2 months ago · MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - businesswire.com